Ketaminhydrochlorid Inresa (Ketamine Hydrochloride)

Ketamine hydrochloride acts primarily as an antagonist at the NMDA receptor, decreasing excitatory neurotransmission in the brain. This blockade produces dissociative anesthesia and analgesia while also interacting with opioid and monoaminergic systems, contributing to its unique cardiovascular and respiratory profile.

The specific dose of Ketaminhydrochlorid Inresa is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and route of administration. Healthcare professionals adjust the amount to achieve the desired anesthetic or analgesic effect while monitoring safety.

Safety data for ketamine in pregnancy and lactation are limited, and the drug is generally classified as contraindicated or used only when the potential benefit outweighs the risk. Clinicians should evaluate each case individually and discuss potential risks with the patient.

To request Ketaminhydrochlorid Inresa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Ketamine differs from many inhalational or intravenous anesthetics by providing dissociative anesthesia while maintaining airway reflexes and stimulating the cardiovascular system. Unlike propofol or volatile agents, it does not cause significant respiratory depression, making it useful in trauma or field settings, though it may produce vivid emergence phenomena.

Ketaminhydrochlorid Inresa should be stored at controlled room temperature, below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations to maintain stability and potency.

The product is supplied as a sterile injectable solution for intramuscular or intravenous administration. Healthcare professionals inject the dose directly into a vein or muscle, following aseptic technique and monitoring the patient’s vital signs throughout the procedure.

Serious risks include severe hypertension, cardiac arrhythmias, respiratory depression (especially when combined with other depressants), persistent hallucinations or delirium, and rare allergic reactions. Continuous monitoring of cardiovascular and respiratory status is essential during and after administration.

Ketamine is contraindicated in patients with uncontrolled hypertension, severe coronary artery disease, known hypersensitivity to the drug, or certain psychiatric conditions such as uncontrolled schizophrenia. Clinicians must assess individual risk factors before initiating therapy.